Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606905 · ClinicalTrials.gov registry record · NA
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
A NA study of Miscarriage, Recurrent and Abortion, Habitual, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT00606905: Completed NA study of Miscarriage, Recurrent and Abortion, Habitual, sponsored by University of Chicago.
NCT00606905 is a NA study of Miscarriage, Recurrent and Abortion, Habitual that has completed, run by University of Chicago. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606905, a NA study of Miscarriage, Recurrent and Abortion, Habitual, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarriage. This study will help in providing an answer to the question of whether IVIG is helpful in secondary recurrent miscarriage.
Conditions Studied
Interventions
- BIOLOGICAL Gamimune N or Gamunex 10%
- OTHER normal saline
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1999-11 |
| Est. Completion | 2010-01 |
| Phase | NA |
What the finished NCT00606905 record still lists
NCT00606905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Miscarriage, Recurrent appearing as the primary indexed condition, and to 2 interventions - of which Gamimune N or Gamunex 10% is the first listed.
NCT00606905 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00606905 about?
NCT00606905 is a clinical study titled "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage". Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarria...
What is the current status of trial NCT00606905?
This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 1999-11. Estimated completion is 2010-01.
What conditions does trial NCT00606905 study?
This clinical trial studies the following conditions: Miscarriage, Recurrent, Abortion, Habitual.
What interventions are being tested in trial NCT00606905?
The interventions under investigation include: Gamimune N or Gamunex 10% (BIOLOGICAL), normal saline (OTHER).
Who is sponsoring clinical trial NCT00606905?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606905 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Miscarriage, Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00606905's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia